JP2004503248A - インフルエンザａウイルスおよび／またはインフルエンザｂウイルスの検出方法 - Google Patents
インフルエンザａウイルスおよび／またはインフルエンザｂウイルスの検出方法 Download PDFInfo
- Publication number
- JP2004503248A JP2004503248A JP2002510708A JP2002510708A JP2004503248A JP 2004503248 A JP2004503248 A JP 2004503248A JP 2002510708 A JP2002510708 A JP 2002510708A JP 2002510708 A JP2002510708 A JP 2002510708A JP 2004503248 A JP2004503248 A JP 2004503248A
- Authority
- JP
- Japan
- Prior art keywords
- influenza
- virus
- saliva
- sample
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000712431 Influenza A virus Species 0.000 title claims abstract description 56
- 241000713196 Influenza B virus Species 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims abstract description 29
- 210000003296 saliva Anatomy 0.000 claims abstract description 86
- 239000000523 sample Substances 0.000 claims abstract description 66
- 238000012360 testing method Methods 0.000 claims abstract description 63
- 238000001514 detection method Methods 0.000 claims abstract description 44
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 14
- 208000015181 infectious disease Diseases 0.000 claims abstract description 14
- 230000001900 immune effect Effects 0.000 claims description 21
- 241000700605 Viruses Species 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 108090001074 Nucleocapsid Proteins Proteins 0.000 claims description 6
- 102000011931 Nucleoproteins Human genes 0.000 claims description 6
- 108010061100 Nucleoproteins Proteins 0.000 claims description 6
- 239000012139 lysis buffer Substances 0.000 claims description 6
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 208000037797 influenza A Diseases 0.000 description 38
- 206010022000 influenza Diseases 0.000 description 30
- 210000003800 pharynx Anatomy 0.000 description 28
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 23
- 241000712461 unidentified influenza virus Species 0.000 description 16
- 208000037798 influenza B Diseases 0.000 description 11
- 238000005070 sampling Methods 0.000 description 11
- 238000010240 RT-PCR analysis Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 230000000241 respiratory effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 229920000742 Cotton Polymers 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 239000012149 elution buffer Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 101710154606 Hemagglutinin Proteins 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
- 101710176177 Protein A56 Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 239000000185 hemagglutinin Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 210000001331 nose Anatomy 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000013610 patient sample Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 102000005348 Neuraminidase Human genes 0.000 description 3
- 108010006232 Neuraminidase Proteins 0.000 description 3
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 3
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 3
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 238000011330 nucleic acid test Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-N dCTP Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000002911 sialidase inhibitor Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- -1 β-octyl Chemical group 0.000 description 2
- IITIZHOBOIBGBW-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole Chemical compound C1=CC=C2N(CC)CSC2=C1 IITIZHOBOIBGBW-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- 206010052437 Nasal discomfort Diseases 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000868182 Thermus thermophilus HB8 Species 0.000 description 1
- 108010020713 Tth polymerase Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010065667 Viral Matrix Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229940071125 manganese acetate Drugs 0.000 description 1
- UOGMEBQRZBEZQT-UHFFFAOYSA-L manganese(2+);diacetate Chemical compound [Mn+2].CC([O-])=O.CC([O-])=O UOGMEBQRZBEZQT-UHFFFAOYSA-L 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10028837A DE10028837A1 (de) | 2000-06-15 | 2000-06-15 | Verfahren zum Nachweis von Influenza A/B-Viren |
| PCT/EP2001/006735 WO2001096595A2 (de) | 2000-06-15 | 2001-06-15 | Verfahren zum nachweis von influenza a/b-viren aus speichel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004503248A true JP2004503248A (ja) | 2004-02-05 |
| JP2004503248A5 JP2004503248A5 (enExample) | 2005-02-03 |
Family
ID=7645396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002510708A Pending JP2004503248A (ja) | 2000-06-15 | 2001-06-15 | インフルエンザａウイルスおよび／またはインフルエンザｂウイルスの検出方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6811971B2 (enExample) |
| EP (1) | EP1297187B2 (enExample) |
| JP (1) | JP2004503248A (enExample) |
| AT (1) | ATE385259T1 (enExample) |
| AU (1) | AU2001278452A1 (enExample) |
| CA (1) | CA2412121C (enExample) |
| DE (2) | DE10028837A1 (enExample) |
| ES (1) | ES2298244T5 (enExample) |
| WO (1) | WO2001096595A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2535713A1 (en) | 2011-06-16 | 2012-12-19 | Fujifilm Corporation | Highly sensitive immunochromatography method and immunochromatography kit |
| US12247950B2 (en) | 2018-12-04 | 2025-03-11 | Murata Manufacturing Co., Ltd. | Virus detection system, virus detection method, and virus detection program |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004028342A2 (en) * | 2002-09-25 | 2004-04-08 | Board Of Regents, The University Of Texas System | Endogenous granzyme b in human non-hematopoietic cells |
| AU2006244460B2 (en) * | 2005-05-06 | 2010-04-08 | Gen-Probe Incorporated | Compositions and assays to detect influenza virus A and B nucleic acids |
| WO2007098184A2 (en) * | 2006-02-21 | 2007-08-30 | Nanogen, Inc. | Methods and compositions for analyte detection |
| US20080208486A1 (en) * | 2006-03-23 | 2008-08-28 | Jari Natunen | Integrated System, Device and Use Thereof |
| US20070238095A1 (en) * | 2006-04-11 | 2007-10-11 | Mayo Foundation For Medical Education And Research , A Minnesota Corporation | Detection of Influenza A Virus |
| US20070238093A1 (en) * | 2006-04-11 | 2007-10-11 | Espy Mark J | Detection of influenza A virus |
| US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
| US20090098527A1 (en) * | 2006-09-12 | 2009-04-16 | Fischer Gerald W | Biological organism identification product and methods |
| US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
| US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
| US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
| FI20060946A0 (fi) * | 2006-10-26 | 2006-10-26 | Glykos Finland Oy | Influenssaviruksen nukleiinihappoja ja peptidejä |
| WO2008057605A2 (en) * | 2006-11-10 | 2008-05-15 | Quidel Corporation | Nuclear protein extraction medium and method of use |
| CA2684213A1 (en) | 2007-04-12 | 2008-10-23 | Regents Of The University Of Minnesota | Ischemia/reperfusion protection compositions and methods of using |
| EP2174957B1 (en) | 2007-06-15 | 2016-03-16 | Xiamen University | Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof |
| US9689031B2 (en) | 2007-07-14 | 2017-06-27 | Ionian Technologies, Inc. | Nicking and extension amplification reaction for the exponential amplification of nucleic acids |
| US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
| US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
| EP3058954B1 (en) | 2007-08-27 | 2017-03-01 | Longhorn Vaccines and Diagnostics, LLC | Immunogenic compositions and methods |
| US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| ES2552858T3 (es) * | 2007-10-01 | 2015-12-02 | Longhorn Vaccines And Diagnostics, Llc | Recogida de muestras biológicas y sistema de transporte y métodos de uso |
| US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
| US20110046001A1 (en) * | 2007-11-20 | 2011-02-24 | Autogenomics, Inc. | Multiplex Assay for Respiratory Viruses |
| US8354230B2 (en) | 2007-12-21 | 2013-01-15 | Quest Diagnostics Investments Inc. | Multiplex detection assay for influenza and RSV viruses |
| WO2009142742A1 (en) * | 2008-05-20 | 2009-11-26 | Cantimer, Inc. | Methods, systems and devices for analyzing a biological fluid sample following ion exchange |
| US20110045458A1 (en) * | 2009-08-20 | 2011-02-24 | Mayo Foundation For Medical Education And Research | Detection of Enterovirus |
| EP3494989B1 (en) | 2012-01-26 | 2025-07-16 | Longhorn Vaccines and Diagnostics, LLC | Composite antigenic sequences and vaccines |
| CA2985652C (en) | 2015-05-14 | 2020-03-10 | Gerald W. FISHER | Rapid methods for the extraction of nucleic acids from biological samples |
| US10307398B2 (en) | 2016-09-20 | 2019-06-04 | Regents Of The University Of Minnesota | Resuscitation composition and methods of making and using |
| GB201703383D0 (en) | 2017-03-02 | 2017-04-19 | Gargle Tech Ltd | Testing for particulates |
| EP4205851A3 (en) | 2018-09-05 | 2023-10-04 | Hero Scientific Ltd | Testing for particulates |
| WO2020095584A1 (ja) * | 2018-11-08 | 2020-05-14 | パナソニックＩｐマネジメント株式会社 | 検出システム及び情報表示システム |
| US11053531B2 (en) | 2019-05-31 | 2021-07-06 | Linda Marie Petter | Tester paper and methods of use thereof for detecting a bacterial infection |
| WO2021181339A1 (en) | 2020-03-11 | 2021-09-16 | Hero Scientific Ltd. | Testing devices |
| CA3202405A1 (en) | 2021-01-06 | 2022-07-14 | Zvi Feldman | Filtration sampling devices |
| US20240302370A1 (en) * | 2021-02-12 | 2024-09-12 | Siemens Healthcare Diagnostics Inc. | Sample lysis reagent compositions and methods of production and use thereof |
| US20240410910A1 (en) * | 2021-07-22 | 2024-12-12 | Assaya Llc | Machine testing quality verification |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2104683C (en) | 1990-12-31 | 2004-06-29 | Avraham Liav | Method for visually detecting the presence of a virus in a clinical specimen |
| FR2708348B1 (fr) | 1993-07-28 | 1995-10-06 | Stago Diagnostica | Procédé de dosage d'une substance immunologique au moyen de particules de latex magnétiques et de particules non-magnétiques. |
| US5714341A (en) | 1994-03-30 | 1998-02-03 | Epitope, Inc. | Saliva assay method and device |
| US6015664A (en) | 1995-11-03 | 2000-01-18 | Mcw Research Foundation | Multiplex PCR assay using unequal primer concentrations to detect HPIV 1,2,3 and RSV A,B and influenza virus A, B |
| EP1010981A1 (de) | 1998-12-18 | 2000-06-21 | Diagor GmbH | Konjugate zum Nachweis von Viren und deren Verwendung |
-
2000
- 2000-06-15 DE DE10028837A patent/DE10028837A1/de not_active Ceased
-
2001
- 2001-06-15 AU AU2001278452A patent/AU2001278452A1/en not_active Abandoned
- 2001-06-15 EP EP01956475.6A patent/EP1297187B2/de not_active Expired - Lifetime
- 2001-06-15 ES ES01956475.6T patent/ES2298244T5/es not_active Expired - Lifetime
- 2001-06-15 AT AT01956475T patent/ATE385259T1/de active
- 2001-06-15 CA CA002412121A patent/CA2412121C/en not_active Expired - Fee Related
- 2001-06-15 JP JP2002510708A patent/JP2004503248A/ja active Pending
- 2001-06-15 US US10/311,523 patent/US6811971B2/en not_active Expired - Lifetime
- 2001-06-15 DE DE50113548T patent/DE50113548D1/de not_active Expired - Lifetime
- 2001-06-15 WO PCT/EP2001/006735 patent/WO2001096595A2/de not_active Ceased
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2535713A1 (en) | 2011-06-16 | 2012-12-19 | Fujifilm Corporation | Highly sensitive immunochromatography method and immunochromatography kit |
| US8716032B2 (en) | 2011-06-16 | 2014-05-06 | Fujifilm Corporation | Highly sensitive immunochromatography method and kit employing protein hydrolysates |
| US12247950B2 (en) | 2018-12-04 | 2025-03-11 | Murata Manufacturing Co., Ltd. | Virus detection system, virus detection method, and virus detection program |
Also Published As
| Publication number | Publication date |
|---|---|
| DE50113548D1 (de) | 2008-03-20 |
| DE10028837A1 (de) | 2001-12-20 |
| EP1297187B1 (de) | 2008-01-30 |
| US6811971B2 (en) | 2004-11-02 |
| ES2298244T3 (es) | 2008-05-16 |
| US20030143530A1 (en) | 2003-07-31 |
| WO2001096595A2 (de) | 2001-12-20 |
| ES2298244T5 (es) | 2014-11-14 |
| EP1297187B2 (de) | 2014-08-13 |
| AU2001278452A1 (en) | 2001-12-24 |
| ATE385259T1 (de) | 2008-02-15 |
| WO2001096595A3 (de) | 2002-05-23 |
| CA2412121A1 (en) | 2002-12-09 |
| CA2412121C (en) | 2009-09-01 |
| EP1297187A2 (de) | 2003-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2412121C (en) | Method for the detection of influenza a/b viruses | |
| Kuypers et al. | Detection and quantification of human metapneumovirus in pediatric specimens by real-time RT-PCR | |
| EP4012050A1 (en) | Composition, kit and method for detecting and typing viruses causing respiratory tract infection and application of composition, kit and method | |
| Andréoletti et al. | Differential detection of rhinoviruses and enteroviruses RNA sequences associated with classical immunofluorescence assay detection of respiratory virus antigens in nasopharyngeal swabs from infants with bronchiolitis | |
| Mizuta et al. | Analysis of monthly isolation of respiratory viruses from children by cell culture using a microplate method: a two-year study from 2004 to 2005 in Yamagata, Japan | |
| Afzal et al. | Absence of detectable measles virus genome sequence in blood of autistic children who have had their MMR vaccination during the routine childhood immunization schedule of UK | |
| CN102337351A (zh) | 一种流感病毒分型检测试剂盒 | |
| Biber et al. | The role of mouthwash sampling in SARS-CoV-2 diagnosis | |
| TWI362419B (en) | Nucleic acid detection | |
| Purohit et al. | Sampling and analytical techniques for COVID-19 | |
| Billaud et al. | Detection of rhinovirus and enterovirus in upper respiratory tract samples using a multiplex nested PCR | |
| CN104212914B (zh) | 埃博拉五重荧光pcr快速超敏检测试剂盒及其应用 | |
| US20240094205A1 (en) | Immunological test for the detection of viral infections | |
| Artik et al. | General evaluation of COVID-19 diagnosis methods | |
| Sareen et al. | Saliva as A Diagnostic Tool for Detection of the Viruses: A Review | |
| Leparc et al. | Search for poliovirus in specimens from patients with the post‐polio syndrome | |
| Kumar et al. | Analytical performances of different diagnostic methods for SARS-CoV-2 virus-A review | |
| WO2022014563A1 (ja) | 簡易鼻腔粘膜表面付着粘液の採取方法および該検体中の被検出物を検出するための検査キット | |
| KR101987844B1 (ko) | 호흡기 바이러스 검출을 위한 프라이머 세트 및 이의 용도 | |
| RU2850880C1 (ru) | Набор олигонуклеотидных праймеров для выявления РНК вируса эпидемического паротита | |
| Valentova et al. | Detection of Bovine Respiratory Syncytial Virus in Cell Cultures by nRT-PCR and Use of the Method for Virus Identification in Clinical Samples | |
| Jalowayski et al. | Peroxidase-antiperoxidase assay for rapid detection of respiratory syncytial virus in nasal epithelial specimens from infants and children | |
| Kanlayanadonkit | Evaluation of the Solana Flu A and B assay for rapid identification and differentiation of Influenza A Virus and Influenza B virus | |
| Krumova et al. | Monkeypox: Significance of Various Clinical Samples, Clinical Manifestation, and Molecular Genetic Analysis–Experience of Bulgaria | |
| Kaore et al. | Laboratory diagnosis of novel H1N1 virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060523 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080108 |